65,437 trials
Head and Neck Cancer
Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants
Cholestasis
Primary: Incidence of Neonatal Cholestasis — 1; 2 Participants
Pain
Primary: Respiratory Depression — 10.9; 10.5 breaths/minute
Heart Valve Diseases
Primary: Late Adverse Event Incidence — 7; 0; 0; 4 event/100-patient years
Pregnancy
Primary: Time to Definitive Diagnosis — 87; 136 minutes
Paranasal Sinus Disease
Primary: Rate of Infection — 113; 113 Participants
Heart Failure
Primary: Impact of Intra-aortic Balloon Pump Activation on Left Ventricular Stroke Work. — 939; 5628; 667; NA mmHg-mL
Hypophosphatemic Rickets, X Linked Dominant
Primary: Area Under the Curve for FGF23 — 3172.34; 3215.34 pg/ml*hr
Pharmacokinetics
Primary: Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use — 12.5; 14.3; 10.9; 42.9 pg/ml
Spinocerebellar Ataxia
Primary: Percent Change From Baseline to Post Treatment on the Scale for the Assessment and Rating of Ataxia (SARA) — -25.9; -27.8 percentage change — p=0.29
Substance Related Disorders · Mental Illness
Primary: MISSION Fidelity Index — 0; 68 percentage of MISSION-Vet staff use
Hyperalgesia, Secondary
Primary: Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups — 1.07; 1.27; 0.74 cm^2 — p=0.48
Depression
Primary: Depression Severity as Assessed by the Montgomery Åsberg Depression Rating Scale (MADRS) Score — 26.4; 29.29; 11.5; 16.3 units on a scale
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Prequit Change in Cigarettes Per Day — -2.6; -3.9 Cigarettes Per Day
Healthy Subjects
Primary: Step Length Adaptation — 83.6 % of step length compensated for